Table 3.
Conventional Histomorphometric Parameters in Study Subjects and Controls
| Parameter | Historical controls (N = 11) | Denosumab subjects (N = 4) |
|---|---|---|
| Cancellous bone | ||
| Eroded surface/bone surface (%) | 5.59 ± 1.88 | 1.99 ± 1.08 |
| Mineralizing surface/bone surface (%) | 5.36 ± 3.89 | 6.73 ± 10.48 |
| Bone formation rate/bone surface (μm3/μm2/year) | 10.60 ± 8.41 | 20.76 ± 27.48 |
| Endocortical bone | ||
| Eroded surface/bone surface (%) | 5.82 ± 2.10 | 2.03 ± 1.14 |
| Mineralizing surface/bone surface (%) | 11.99 ± 9.28 | 11.10 ± 13.41 |
| Bone formation rate/bone surface (μm3/μm2/year) | 28.89 ± 24.75 | 28.52 ± 37.61 |
| Periosteal bone | ||
| Mineralizing surface/bone surface (%) | 20.91 ± 10.25 | 15.97 ± 14.84 |
| Bone formation rate/bone surface (μm3/μm2/year) | 73.42 ± 33.45 | 66.37 ± 54.72 |
All values shown are mean ± SD.
N = number of subjects with an evaluable biopsy for fluorochrome labeling.